Opioid receptor blockade increases the number of lymphocytes without altering T cell response in draining lymph nodes in vivo

Journal of Neuroimmunology

Volumn 188, Issue 1-2, 2007, Pages 95-102

  Jaume, Martial ^a,b   Laffont, Sophie ^a,b   Chapey, Emmanuelle ^a,b   Blanpied, Catherine ^a,b   Dietrich, Gilles ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

CD4+ T cells; Cell proliferation; Lymph nodes; Mice; Opioids

Indexed keywords

CHEMOKINE; DELTA OPIATE RECEPTOR; FAS ANTIGEN; OPIATE ANTAGONIST;

ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; HOMEOSTASIS; IN VIVO STUDY; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SENSITIVITY ANALYSIS; SYNTHESIS; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD95; CD4-POSITIVE T-LYMPHOCYTES; CELL DEATH; CELL PROLIFERATION; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENES, MHC CLASS II; IMMUNOGLOBULIN G; LYMPH NODES; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NALTREXONE; NARCOTIC ANTAGONISTS; OVALBUMIN; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, OPIOID;

EID: 34547132099     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.06.013     Document Type: Article

References (44)

1. Bayer B.M., Daussin S., Hernandez M., and Irvin L. Morphine inhibition of lymphocyte activity is mediated by an opioid dependent mechanism. Neuropharmacology 29 (1990) 369-374
2. + T cell priming by dendritic cells in intact lymph nodes. Nat. Immunol. 4 (2003) 579-585
3. Bryant H.U., Bernton E.W., and Holaday J.W. Morphine pellet-induced immunomodulation in mice: temporal relationships. J. Pharmacol. Exp. Ther. 245 (1988) 913-920
4. Campbell J.J., and Butcher E.C. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr. Opin. Immunol. 12 (2000) 336-341
5. Eisenstein T.K., and Hilburger M.E. Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. J. Neuroimmunol. 83 (1998) 36-44
6. Esche C., Makarenkova V.P., Kost N.V., Lotze M.T., Zozulya A.A., and Shurin M.R. Murine dendritic cells express functional delta-type opioid receptors. Ann. N. Y. Acad. Sci. 885 (1999) 387-390
7. Flores C.M., Hernandez M.C., Hargreaves K.M., and Bayer B.M. Restraint stress-induced elevations in plasma corticosterone and beta-endorphin are not accompanied by alterations in immune function. J. Neuroimmunol. 28 (1990) 219-225
8. Flores L.R., Hernandez M.C., and Bayer B.M. Acute immunosuppressive effects of morphine: lack of involvement of pituitary and adrenal factors. J. Pharmacol. Exp. Ther. 268 (1994) 1129-1134
9. Forster R., Schubel A., Breitfeld D., Kremmer E., Renner-Muller I., Wolf E., and Lipp M. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99 (1999) 23-33
10. Foucras G., Gapin L., Coureau C., Kanellopoulos J.M., and Guery J.C. Interleukin 4-producing CD4 T cells arise from different precursors depending on the conditions of antigen exposure in vivo. J. Exp. Med. 191 (2000) 683-694
11. Gaveriaux C., Peluso J., Simonin F., Laforet J., and Kieffer B. Identification of κ and δ receptor transcripts in immune cells. FEBS Lett. 369 (1995) 272-276
12. Gaveriaux-Ruff C., Matthes H.W.D., Peluso J., and Kieffer B.L. Abolition of morphine-immunosuppression in mice lacking the μ-opioid receptor gene. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 6326-6330
13. Gaveriaux-Ruff C., Filliol D., Simonin F., Matthes H.W., and Kieffer B.L. Immunosuppression by delta-opioid antagonist naltrindole: delta- and triple mu/delta/kappa-opioid receptor knockout mice reveal a nonopioid activity. J. Pharmacol. Exp. Ther. 298 (2001) 1193-1198
14. Gaveriaux-Ruff C., Simonin F., Filliol D., and Kieffer B. Enhanced humoral response in kappa-opioid receptor knockout mice. J. Neuroimmunol. 134 (2003) 72-81
15. Haskins K., Kubo R., White J., Pigeon M., Kappler J., and Marrack P. The major histocompatibility complex-restricted antigen receptor on T cells. I. Isolation with a monoclonal antibody. J. Exp. Med. 157 (1983) 1149-1169
16. Hernandez M.C., Flores L.R., and Bayer B.M. Immunosuppression by morphine is mediated by central pathways. J. Pharmacol. Exp. Ther. 267 (1993) 1336-1341
17. Ishimaru N., Yanagi K., Ogawa K., Suda T., Saito I., and Hayashi Y. Possible role of organ-specific autoantigen for Fas ligand-mediated activation-induced cell death in murine Sjogren's syndrome. J. Immunol. 167 (2001) 6031-6037
18. Jaume M., Jacquet S., Cavailles P., Mace G., Stephan L., Blanpied C., Demur C., Brousset P., and Dietrich G. Opioid receptor blockade reduces Fas-induced hepatitis in mice. Hepatology 40 (2004) 1136-1143
19. Kieffer B.L., and Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog. Neurobiol. 66 (2002) 285-306
20. Kraus J., Borner C., Giannini E., Hickfang K., Braun H., Mayer P., Hoehe M.R., Ambrosch A., Konig W., and Hollt V. Regulation of mu-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site. J. Biol. Chem. 276 (2001) 43901-43908
21. Kraus J., Borner C., Giannini E., and Hollt V. The role of nuclear factor kappaB in tumor necrosis factor-regulated transcription of the human mu-opioid receptor gene. Mol. Pharmacol. 64 (2003) 876-884
22. Kraus J., Borner C., Lendeckel U., and Hollt V. Interferon-gamma down-regulates transcription of the mu-opioid receptor gene in neuronal and immune cells. J. Neuroimmunol. 181 (2006) 13-18
23. Lyons A.B. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J. Immunol. Methods 243 (2000) 147-154
24. Lysle D.T., Coussons M.E., Watts V.J., Bennett E.H., and Dykstra L.A. Morphine-induced alterations of immune status: dose dependency, compartment specificity and antagonism by naltrexone. J. Pharmacol. Exp. Ther. 265 (1993) 1071-1078
25. Madden J.J., Whaley W.L., and Ketelsen D. Opiate binding sites in the cellular immune system: expression and regulation. J. Neuroimmunol. 83 (1998) 57-62
26. Madden J.J., Whaley W.L., Ketelsen D., and Donahoe R.M. The morphine-binding site on human activated T-cells is not related to the mu opioid receptor. Drug Alcohol Depend. 62 (2001) 131-139
27. Makarenkova V.P., Esche C., Kost N.V., Shurin G.V., Rabin B.S., Zozulya A.A., and Shurin M.R. Identification of delta- and mu-type opioid receptors on human and murine dendritic cells. J. Neuroimmunol. 117 (2001) 68-77
28. Mellon R.D., and Bayer B.M. Evidence for central opioid receptors in the immunomodulatory effects of morphine: review of potential mechanism(s) of action. J. Neuroimmunol. 83 (1998) 19-28
29. + T cells. J. Immunol. 157 (1996) 5324-5328
30. Nguyen K., and Miller B.C. CD28 costimulation induces delta opioid receptor expression during anti-CD3 activation of T Cells. J. Immunol. 168 (2002) 4440-4445
31. Philippe D., Dubuquoy L., Groux H., Brun V., Chuoi-Mariot M.T., Gaveriaux-Ruff C., Colombel J.F., Kieffer B.L., and Desreumaux P. Anti-inflammatory properties of the mu-opioid receptor support its use in the treatment of colon inflammation. J. Clin. Invest. 111 (2003) 1329-1338
32. Robertson J.M., Jensen P.E., and Evavold B.D. DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope. J. Immunol. 164 (2000) 4706-4712
33. Rot A., and von Andrian U.H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 22 (2004) 891-928
34. Sacerdote P., Manfredi B., Gaspani L., and Panerai A. The opioid antagonist naloxone induces a shift from type 2 to type 1 cytokine pattern in BALB/cJ mice. Blood 95 (2000) 2031-2036
35. Sallusto F., Mackay C.R., and Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18 (2000) 593-620
36. Shahabi N.A., McAllen K., Matta S.G., and Sharp B.M. Expression of delta opioid receptors by splenocytes from SEB-treated mice and effects on phosphorylation of MAP kinase. Cell. Immunol. 205 (2000) 84-93
37. Sharp B.M. Opioid receptor expression and function. J. Neuroimmunol. 147 (2004) 3-5
38. + T cells and DOR-dependent suppression of HIV-1 expression. J. Immunol. 167 (2001) 1097-1102
39. Sozzani S., Luini W., Borsatti A., Polentarutti N., Zhou D., Piemonti L., D'Amico G., Power C.A., Wells T.N., Gobbi M., Allavena P., and Mantovani A. Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J. Immunol. 159 (1997) 1993-2000
40. Sun P., and Loh H.H. Transcriptional regulation of mouse delta-opioid receptor gene. Role of Ikaros in the stimulated transcription of mouse delta-opioid receptor gene in activated T cells. J. Biol. Chem. 277 (2002) 12854-12860
41. Wang J., Charboneau R., Barke R.A., Loh H.H., and Roy S. Mu-opioid receptor mediates chronic restraint stress-induced lymphocyte apoptosis. J. Immunol. 169 (2002) 3630-3636
42. Wick M.J., Minnerath S.R., Roy S., Ramakrishnan S., and Loh H.H. Differential expression of opioid receptor genes in human lymphoid cell lines and peripheral blood lymphocytes. J. Neuroimmunol. 64 (1996) 29-36
43. Yin D., Mufson A., Wang R., and Shi Y. Fas-mediated cell death promoted by opioids. Nature 397 (1999) 218
44. Yin D., Tuthill D., Mufson R., and Shi Y. Chronic restraint stress promotes lymphocyte apoptosis by modulating CD95 expression. J. Exp. Med. 191 (2000) 1423-1428